A direct-acting antiviral drug abrogates viremia in Zika virus-infected rhesus macaques
- 10 June 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (547)
- https://doi.org/10.1126/scitranslmed.aau9135
Abstract
Zika virus infection in humans has been associated with serious reproductive and neurological complications. At present, no protective antiviral drug treatment is available. Here, we describe the testing and evaluation of the antiviral drug, galidesivir, against Zika virus infection in rhesus macaques. We conducted four preclinical studies in rhesus macaques to assess the safety, antiviral efficacy, and dosing strategies for galidesivir (BCX4430) against Zika virus infection. We treated 70 rhesus macaques infected by various routes with the Puerto Rico or Thai Zika virus isolates. We evaluated galidesivir administered as early as 90 min and as late as 72 hours after subcutaneous Zika virus infection and as late as 5 days after intravaginal infection. We evaluated the efficacy of a range of galidesivir doses with endpoints including Zika virus RNA in plasma, saliva, urine, and cerebrospinal fluid. Galidesivir dosing in rhesus macaques was safe and offered postexposure protection against Zika virus infection. Galidesivir exhibited favorable pharmacokinetics with no observed teratogenic effects in rats or rabbits at any dose tested. The antiviral efficacy of galidesivir observed in the blood and central nervous system of infected animals warrants continued evaluation of this compound for the treatment of flaviviral infections.This publication has 34 references indexed in Scilit:
- Detection of Zika virus in salivaJournal of Clinical Virology, 2015
- Modelling hepatitis C therapy—predicting effects of treatmentNature Reviews Gastroenterology & Hepatology, 2015
- Potential Sexual Transmission of Zika VirusEmerging Infectious Diseases, 2015
- Detection of Zika Virus in UrineEmerging Infectious Diseases, 2015
- BCX4430, a Novel Nucleoside Analog, Effectively Treats Yellow Fever in a Hamster ModelAntimicrobial Agents and Chemotherapy, 2014
- Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430Nature, 2014
- Probable Non–Vector-borne Transmission of Zika Virus, Colorado, USAEmerging Infectious Diseases, 2011
- Zika Virus Outbreak on Yap Island, Federated States of MicronesiaThe New England Journal of Medicine, 2009
- Transmission of Schistosoma haematobium by Bulinus sp. in the KE district of the Gold CoastTransactions of the Royal Society of Tropical Medicine and Hygiene, 1956
- Zika Virus (I). Isolations and serological specificityTransactions of the Royal Society of Tropical Medicine and Hygiene, 1952